At the end of 2023, the FDA approved Casgevy for sickle cell disease, its first approval for a therapeutic that used the genome editing tool clustered regulatory interspaced palindromic repeats ...

In a new study published in the Clinical and Translational Medicine, the research group of Prof. Chen-Yu Zhang and Prof. Xi Chen at Nanjing University evaluated the on- and off-target effects of ...

CRISPR-Cas9 is a nuclease-based genome editing system which has seen exponential growth in adoption with broad applications from basic research to therapeutics. CRISPR mediated genome editing is an ...

CRISPR-Cas9 gene editing technology is widely used to to help study genes of interest and modify disease-associated genes. However, the system is associated with adverse effects, including mutations ...

Researchers have discovered that a chemical modification to the synthetic messenger RNA used in therapeutics can cause the cell’s machinery to misread its instructions and result in unintended immune ...

Thought LeadersDr. Amir SheikhiAssistant ProfessorChemical Engineering and Biomedical EngineeringThe Pennsylvania State University AZoNano speaks with Dr. Amir Sheikhi from The Pennsylvania State ...

Clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) have transformed genome engineering techniques. Numerous toolsets have been created to enable easy and efficient ...

Transfection is a method used to introduce nucleic acids into mammalian and insect cells. This technique has been used for a wide variety of applications involving protein expression and/or gene ...

Researchers have discovered how drugs can affect various membrane-spanning proteins in addition to their intended target, potentially causing unwanted side effects. The results illuminate one of the ...

In this Interview, NewsMedical speaks with Amy Landreman about NanoBRET® Technology and its role in cellular target engagement. Could you start by explaining the significance of understanding cellular ...